Colorectal cancer (CRC) is the third most common tumour worldwide and represents the second leading cause of cancer death in Europe and the USA. Approximately 20% of CRC patients will present distant metastasis (stage IV) at the time of diagnosis with 5-year survival \<10% ([@bib14]). Management of metastatic CRC (mCRC) has substantially evolved over the past decade with the introduction of new chemotherapy combinations and biological agents. The US Food and Drug Administration approved the anti-vascular endothelial growth factor (VEGF) antibody bevacizumab for first-line treatment of patients with mCRC in 2004 ([@bib13]). Since its approval, bevacizumab in combination with chemotherapy has become the standard first-line treatment option in mCRC, extending both progression-free survival (PFS) and overall survival (OS) ([@bib13]; [@bib16]; [@bib27]). Despite clinical use of bevacizumab for nearly a decade, however, important questions still remain, including the prediction and management of potential adverse effects and selection of the ideal patients\' population. In this regard, predictive biomarkers of response are still not available, although a number of potential systemic, circulating, tissue and imaging biomarkers have emerged from recently completed clinical trials ([@bib15]).

Observations in patients ([@bib8]; [@bib21]) and preclinical findings ([@bib23]) both suggest that VEGF blockade may perturb the energy balance of cancer cells. Several groups have looked at metabolic perturbations associated with anti-angiogenic therapy by using either magnetic resonance spectroscopy ([@bib18]) or hyperpolarised 13C magnetic resonance spectroscopy ([@bib2]), reporting increased lactate levels and production of labelled malate from fumarate, an early indicator of cell necrosis. In line with these findings, we showed for the first time that anti-VEGF therapy causes metabolic perturbations in experimental tumours, including marked reduction in glucose and ATP levels ([@bib23]). Moreover, probably as consequence of marked glucose depletion and exhaustion of ATP levels, we also observed that anti-angiogenic therapy increased AMP-activated protein kinase (AMPK) activation in tumour xenografts and that tumour cells lacking AMPK activity undergo marked tumour necrosis following a short-term course of anti-VEGF therapy ([@bib23]).

AMPK is a heterotrimeric serine/threonine protein kinase, and is activated following its phosphorylation by its upstream kinase liver kinase B1 (LKB1) (also known as STK11) in response to an increase in cellular AMP/ATP ratio ([@bib29]). AMPK has a central role in the regulation of energy metabolism in all eukaryotes, and governs glucose and lipid metabolism in response to alterations in nutrients and intracellular energy levels, contributing to maintain the steady-state levels of intracellular ATP ([@bib11]). Phosphorylation of acetyl-CoA carboxylases by AMPK contributes to regulation of fatty acid metabolism ([@bib11]) and is considered an indirect read-out of AMPK activation. We hypothesise that the integrity of signalling pathways involved in the control of cell metabolism, growth and quiescence, such as AMPK, could be important to sense changes in the tumour microenvironment caused by angiogenesis inhibition and to enable tumour cells adaptation. Accordingly, tumour cells lacking AMPK activity are expected to undergo necrosis following anti-angiogenic therapy, due to their incapacity to maintain ATP levels. Although in patients the association between tumour necrosis and outcome of anti-angiogenic therapy is not firmly established, in preclinical models necrosis often leads to increased recruitment into tumours of macrophages and other specialised subsets of myeloid cells which can promote tumour angiogenesis and leads to escape from VEGF blockade ([@bib9]). Therefore, defective AMPK activity might be predicted to associate initially with improved tumour response, followed by increased resistance to VEGF neutralisation.

Several studies investigated the prognostic role of AMPK in human malignancies, including colorectal, lung, ovarian, gastric cancer, renal cell carcinoma and hepatocarcinoma ([@bib1]; [@bib30]; [@bib3]; [@bib17]; [@bib32]; [@bib33]). In most of these studies---except gastric cancer ([@bib17])---low levels of AMPK activation correlated with poor prognosis. With regard to targeted therapy, one study reported that low phosphorylated AMPK (pAMPK) levels are associated with poor response to bevacizumab and interferon-*α* therapy in renal cell carcinoma ([@bib30]). Based on this rationale and the paucity of studies investigating the predictive value of AMPK activation in patients treated with anti-angiogenic drugs, we designed a pilot retrospective study to analyse activation of the AMPK pathway in CRC patients treated with bevacizumab plus chemotherapy and to correlate it with patient clinical data and survival.

Materials and methods
=====================

Patients and treatments
-----------------------

Study design and tissue analysis were approved by the institutional review board of Istituto Oncologico Veneto. Our study cohort was generated through a query in our patients\' files for all patients with mCRC who received between January 2007 to May 2011 FOLFIRI-bevacizumab as a first-line treatment. This regimen consists of bi-weekly cycles of irinotecan (180 mg m^−2^), bevacizumab (5 mg kg^−1^) and a bolus of 5-FU (400 mg m^−2^) followed by a 46 h continuous infusion of the same drug (2400 mg m^−2^).

Clinical information was extracted from patients\' medical records. Inclusion criteria comprised pathology-confirmed adenocarcinoma of the colon or rectum in a TNM stage IV with availability of samples of the primary carcinoma retrieved before beginning of the anti-angiogenic therapy. A total of 48 patients met all inclusion criteria and comprised the patient study cohort. Collected variables were related to demography, tumour location, number and location of metastasis, their synchronous or metachronous nature, surgery of the primary tumour and of metastasis, adjuvant chemotherapy, *KRAS* status, Eastern Cooperative Oncology Group (ECOG) performance status (PS) and carcino-embrionic antigen (CEA) levels in the blood at the beginning of first-line therapy.

Radiological response during treatment was evaluated by computerised tomography scan of the chest and abdomen conducted every 2--3 months and was classified using Response Evaluation Criteria In Solid Tumours (RECIST) 1.1 criteria ([@bib7]). Survival data were obtained from patient medical records. Information on subsequent lines of chemotherapy was also retrieved.

Immunohistochemical staining
----------------------------

Immunohistochemistry (IHC) analysis was conducted in 5-*μ*m-thick paraffin-embedded tumour sections, dewaxed in xylene and re-hydrated in progressively less concentrated alcohol solutions.

To evaluate the status of the AMPK pathway, slides were incubated with rabbit anti-pAMPK monoclonal antibody (Thr172, Cell Signaling Technology, Danvers, MA, USA), anti-phosphorylated acetyl-Coa carboxylase (pACC) polyclonal antibody (Ser79, Cell Signaling Technology) and anti-LKB1 policlonal antibody (Ley 37D/G6, Santa Cruz Biotechnology, Dallas, TX, USA), according to the manufacturer\'s instructions. Ethylene diaminetetraacetic acid disodium salt dihydrate, pH 8 (1 m[M]{.smallcaps}) for 45 min was used as a standard microwave-based antigen retrieval method for all antigens, except for LKB1. Citric acid buffer, pH 6.0 (10 m[M]{.smallcaps}) for 20 min at 94 °C was used for LKB1 antigen retrieval. Staining conditions for pAMPK (1 : 150 dilution) and pACC (1 : 200 dilution) were previously reported ([@bib23]). IHC was performed using a DAKO autostainer (Glostrup, Denmark), according to the manufacturer\'s protocol. For LKB1, after blocking the endogenous peroxidase, tissue sections were incubated with 5% normal goat serum in 0.1% Tween-20 tris-buffered saline buffer, pH 7.6 (60 min). Primary anti-LKB1 (1 : 100) antibody was incubated overnight at 4 °C. Sections were subsequently incubated with biotinylated anti-rabbit or anti-mouse antibody for 30 min, followed by Vectastain ABC reagent (Vector Labs, Peterborough, UK) for additional 30 min. Liquid diaminobenzidine (DAB; DAKO) was used as a chromogenic agent for 10 min and sections were counter-stained with Mayer\'s haematoxylin. Between each immunostaining step, slides were briefly washed in Tween-20 tris-buffered saline. Specificity of each staining procedure was confirmed by replacing the primary antibody with PBS. Based on previous work ([@bib23]), sections of IGROV-1 and OC316 tumour xenografts treated with anti-VEGF monoclonal antibody (mAb) were included as positive and negative controls for pAMPK and pACC, respectively ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}). To setup IHC for LKB1, tumour xenografts formed by A549 cells---which lack LKB1 expression ([@bib28])---were analysed as a negative control. As a positive control, xenografts formed by A549 cells reconstituted with LKB1 cDNA were analysed ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}).

IHC staining was evaluated by two experienced pathologists (GE and CM) with no prior knowledge of clinical data. In case of disagreement, results were discussed in a multi-headed microscope, and a consensus was reached. Assessment was conducted at a magnification of × 100, on the basis of the Quick Score Method ([@bib10]). Immunoreactivity was scored semi-quantitatively for both the intensity and the proportion of cells staining: intensity was given scores 0--3 (no staining 0, light staining 1, moderate staining 2 and strong staining 3) and proportion was given scores 1--6 (0--4% 1, 5--20% 2, 21--40% 3, 41--60% 4, 61--80% 5 and 81--100% 6). The two scores were multiplied to obtain the final score (range 0--18). Concordance between the two observers was evaluated by the weighted kappa coefficient. The weighted kappa coefficient was 0.660 for pAMPK, 0.719 for pACC and 0.9114 for LKB1 score, indicating good agreement between the pathologists. For statistical analysis, samples with pAMPK, pACC or LKB1 score ⩽5 were grouped in one group and were compared with those with score \>5. This cutoff was chosen as it was found to best stratify samples with strong/moderate *vs* light/negative staining.

Clinical endpoints and statistical analysis
-------------------------------------------

Endpoint of the study was to determine the association between pAMPK protein expression and OS or PFS. The association between pACC protein expression and OS or PFS was also assessed. OS was defined as the time from date of first-line treatment to date of death or to last follow-up for censored data. PFS was calculated from the beginning of therapy with FOLFIRI-bevacizumab to the date of first disease progression, or death from all causes or censored at the last documented follow-up date.

To verify the reliability of IHC in assessing the activation of the AMPK pathway, we tested the correlation between pAMPK and pACC scores on the same tumour sample, using the Spearman\'s coefficient. The statistical significance of association between pACC/pAMPK score (⩽5 *vs* \>5) and clinical-pathological data was assessed by Fisher\'s exact test.

The survival probability was estimated by means of the Kaplan--Meier method, and heterogeneity in survival among strata of selected variables was assessed through the log-rank test. A multivariate Cox proportional hazards model was applied to identify factors that were associated with the risk of death. A Collett\'s Model Selection approach ([@bib5]) was used with a level of significance of 0.2 at univariate analysis and stay and entry criterions of 0.1 to build up multivariate models. To check the proportional hazards assumption, a score process (which is a transformed partial sum process of the martingale residuals) was compared with the simulated processes under the null hypothesis that the proportional hazards assumption holds ([@bib20]). Multivariate hazard ratios (HRs), with their 95% confidence intervals (CIs), were computed. Two separate models were performed as the correlation between pACC and pAMPK scores did not allow to include them in a single model simultaneously. The Kaplan--Meier method was computed to estimate the survival probability from progression to death or last follow-up. Data analyses were performed using the SAS statistical package (SAS, release 9.2; SAS Institute, Cary, NC, USA).

Results
=======

Patient characteristics
-----------------------

Clinical data of the 48 patients enrolled in this study are listed in [Table 1](#tbl1){ref-type="table"}. The mean (median) age at diagnosis was 63.5 (64.9) years with a range from 28 to 74 years, and 29 patients (60.4%) were male. The mean (median) age at first-line treatment of patients was 64.2 (66.0) years with a range from 29 to 76 years. Fourteen patients (29.2%) had rectal cancer, whereas thirty-two patients (66.7%) had colon cancer. Two patients presented a concomitant double primary tumour of the colon and rectum. Thirty-nine patients (81.2%) had metastatic disease at diagnosis, whereas nine patients (18.7%) developed metachronous metastases. Sixteen patients (33.3%) had exclusively liver metastases. Thirty-six patients (75.0%) had a performance status of 0 when first-line chemotherapy began. Blood levels of CEA were evaluated before starting chemotherapy, showing an average value of 291 (0.5--6762) *μ*g l^−1^. *KRAS* status was assessed on tumour samples from 46 patients and 24 of them (52.2%) presented mutations in exons 12 or 13. Twenty-eight patients (58.3%) underwent surgery of metastases or loco-regional treatment with radical intent (such as microwaves or radiofrequencies of hepatic lesions). Thirty-nine patients underwent two or more lines of chemotherapy (including re-challenge with the same drugs) after progression under FOLFIRI-bevacizumab treatment.

pAMPK and pACC expression in CRC
--------------------------------

We performed IHC of pAMPK to investigate the LKB1/AMPK pathway activation in tumour sections. Phosphorylation of acetyl-CoA carboxylases, a direct downstream target of AMPK, was also analysed. In general, pACC and pAMPK expression was detected in the cytoplasm of tumour cells ([Figure 1](#fig1){ref-type="fig"}). The Spearman\'s coefficient for the correlation between pAMPK and pACC scores in primary tumour samples was 0.514 (*P*=0.0002).

Fourteen patients (29.2%) were included in the pAMPK-negative group (score ⩽5), whereas thirty-four patients (70.8%) were included in the pAMPK-positive group (score \>5). Moreover, there were 15 (31.2%) and 33 (68.7%) patients in the pACC-negative (score ⩽5) and -positive (score \>5) groups, respectively. A very good correlation between pACC and pAMPK scores was also observed in metastatic tumour samples (Spearman\'s coefficient=0.848, *P*\<0.0001). However, due to the limited number of paired samples available (*n*=17), we were unable to investigate the predictive/prognostic value of the pAMPK and pACC scores assessed in metastasis.

We found no statistically significant association between age, gender, primary and metastatic tumour site, *KRAS* status, CEA blood levels, number of lines of chemotherapy and the high- and low-pAMPK or pACC expression groups ([Table 1](#tbl1){ref-type="table"}). A significant association was found between pACC score and surgery of metastasis, as a higher number of patients underwent surgery in the pACC-positive compared with the pACC-negative group, and between pACC score and ECOG performance status ([Table 1](#tbl1){ref-type="table"}).

LKB1 expression in CRC
----------------------

We next investigated whether samples lacking pAMPK expression showed alterations in LKB1, the kinase upstream of AMPK in mammalian cells ([@bib29]). Due to the limited amount of samples available, analysis was limited to 11 tumour samples disclosing low levels of pAMPK expression and to additional three samples with high levels of pAMPK expression. By using the same scoring system used for pAMPK and pACC, we found low LKB1 expression (score ⩽5) in 8 out of 11 samples analysed, whereas the remaining three samples showed moderate LKB1 expression ([Figure 2](#fig2){ref-type="fig"}). However, completely absent LKB1 expression was found only in two samples. Conversely, LKB1 was expressed at moderate--high levels in all samples showing high pAMPK that were included in this analysis ([Figure 2](#fig2){ref-type="fig"}). In conclusion, reduced LKB1 expression is found in the majority of CRC samples bearing low pAMPK levels.

Survival according to pAMPK and pACC expression
-----------------------------------------------

Among the forty-eight patients, forty-six disease progressions (95.8%) were documented and twenty-six patients (54.2%) died during follow-up. With a median follow-up of 24.5 months (4.0--56.5), the median PFS was 10.6 months (2.2--51.5), whereas median OS was 32.9 months (12.2--56.5); estimated 1-year OS rate was 85.4% (95% CI: 71.8--92.8%). Low expression of pAMPK was associated with worse OS. Estimated 1-year OS for pAMPK-negative patients was 71.4% (95% CI: 40.6--88.2%), whereas for pAMPK-positive patients was 91.2% (95% CI: 75.1--97.1%). Although patients with pAMPK-positive tumours showed a significantly improved OS compared with patients with pAMPK-negative tumours (*P*=0.0002), pAMPK status was not significantly associated with PFS (*P*=0.23) ([Figure 3A](#fig3){ref-type="fig"}). Consistently with these results, low pACC expression was associated with worse OS. Estimated 1-year OS for patients with low pACC expression was 66.7% (95% CI: 37.5--84.5%) *vs* 93.9% (95% CI: 77.9--98.4%) for patients with high pACC expression (*P*=0.0007). Moreover, pACC status was significantly associated with PFS (*P*=0.01), as low pACC expression was associated with shorter PFS ([Figure 3B](#fig3){ref-type="fig"}).

Among other parameters considered, ECOG performance status (*P*=0.001), resection of metastases (*P*=0.001), multiple lines of chemotherapy (*P*=0.050) and low blood CEA levels (*P*=0.004) were associated with higher estimated 1-year OS ([Table 2](#tbl2){ref-type="table"}).

Multivariate analysis, performed on 47 patients with all data available, disclosed that pAMPK-negative samples were associated with at higher risk of death than pAMPK-positive samples (HR=6.53; 95% CI: 2.61--16.37; *P*\<0.0001). Risk of death was also related with ECOG performance status (HR=2.70, 95% CI: 1.13--6.48; *P*=0.026), baseline CEA blood values (HR=3.35, 95% CI: 1.38--8.15; *P*=0.008) and number of lines of treatment received (HR=4.21; 95% CI: 1.49--11.94; *P*=0.007) ([Table 3](#tbl3){ref-type="table"}).

Furthermore, low pACC expression was associated with higher risk of death (HR=4.34; 95% CI: 1.86--10.17; *P*=0.0007) as were other parameters, including baseline CEA blood value (HR=3.56, 95% CI: 1.56--8.13; *P*=0.003) and lines of treatment received (HR=4.15; 95% CI: 1.52--11.38; *P*=0.006) ([Table 3](#tbl3){ref-type="table"}). Resection of metastasis and ECOG performance status were not included in this model, because correlation between variables was detected (*P*=0.004 and *P*=0.031, respectively).

Discussion
==========

Angiogenesis is required for growth of solid tumours and its inhibition through pharmaceutical blockade of the VEGF pathway is a therapeutic strategy clinically validated in various human malignancies ([@bib12]). In spite of much efforts, however, the fine mechanisms of tumour regression caused by angiogenesis inhibition remain substantially unknown and validated biomarkers aiding selection of those patients who are most likely to benefit from anti-angiogenic treatment are currently not available ([@bib15]). Previous studies mainly focused on expression of circulating angiogenesis-related biomarkers, such as plasma levels of short VEGF-A isoforms or modified expression of VEGF receptors (VEGFR1 or NRP1) either in plasma or in tumours or genetic markers, including polymorphisms of VEGF-A, VEGFR1, VEGFR2 and IL-8 (reviewed in: ([@bib19])). Among tumour-related biomarkers, genotyping *KRAS* and *BRAF* mutations in CRC has been performed but failed to reveal any differential effects ([@bib26]).

Our study was grounded on the assumption that the capacity of tumour cells to adapt to metabolic changes could influence the outcome of anti-angiogenic therapy. Based on preclinical studies by our group, which showed that anti-VEGF therapy causes marked reduction in glucose levels in the tumour microenvironment followed by activation of the energy sensor AMPK ([@bib23]), we investigated the possible impact of AMPK activation on the response to chemotherapy plus bevacizumab in cancer patients. We focused on CRC because inhibition of tumour angiogenesis through bevacizumab represents a cornerstone in the treatment of mCRC, extending both PFS and OS when used in association with chemotherapy in first or second line of treatment ([@bib13]; [@bib16]; [@bib27]). With regard to AMPK activity, although genetic defects involving the upstream kinase LKB1 are uncommon in this malignancy ([@bib4]), a previous retrospective study on population databases reported expression of pAMPK in 57% of CRC samples ([@bib1]), suggesting that this pathway could be epigenetically silenced in a subset of tumour samples. This study, however, did not analyse expression of other components of the pathway, such as pACC or LKB1, nor did it evaluate the possible predictive role of these biomarkers in response to anti-VEGF therapy.

Low expression of either pAMPK or pACC in the primary tumour significantly correlated with OS both in univariate and multivariate analyses, suggesting a prognostic role of AMPK pathway activation in advanced stage CRC. This result is in line with the observation that expression of these two markers in primary tumours showed a moderate correlation (Spearman\'s coefficient=0.514; *P*=0.0002). Moreover, this finding is consistent with preclinical data suggesting a tumour suppressor role for AMPK in the regulation of cell proliferation and apoptosis by p53, and in the inhibition of cell growth and protein synthesis through inactivation of mTOR ([@bib31]). In line with this hypothesis, clinical studies reported that low AMPK or pAMPK expression is related to a worse survival in several human malignancies ([@bib10]; [@bib3]; [@bib32]). In CRC, however, [@bib1] did not observe a significant impact of the activation of AMPK on survival. Notably, that study considered CRC patients at every stage and patients with stage IV CRC were only 14% of the study population. The study also showed that activation of the AMPK pathway had a significant impact on survival only in the subpopulation of patients that had a pMAPK3/1-positive tumour, representing 30% of the total samples analysed ([@bib1]). Thus it is possible that variables including tumour stage and levels of pMAPK3/1 expression might explain the discrepancy between these two studies regarding the prognostic significance of pAMPK.

With regard to the possibility that AMPK activation could represent a predictive biomarker, it should be noted that the study design does not allow to assess this, as all patients received FOLFIRI plus bevacizumab. Interestingly, pACC status showed a significant association with PFS. This may be due to the strong association between pACC status and surgery or loco-regional treatment of metastasis, which may induce a difference in PFS between pACC-positive and -negative groups. The association between pathway status and radical treatment of metastasis may possibly be explained by the prognostic role of the AMPK pathway.

The low OS of pAMPK-negative patients in the absence of differences in terms of PFS after FOLFIRI-bevacizumab may suggest an impact of AMPK status on tumour response to subsequent lines of therapy. This observation is intriguing because of some preclinical studies that suggested that cancer cells may acquire a more aggressive phenotype during anti-angiogenic treatment ([@bib6]; [@bib24]). In clinical practice, when disease progression is observed it might be more rapid after such treatment, leading to a shortened post-progression survival time. This issue, however, remains highly controversial. In fact, a recent meta-analysis found no differences in the time from discontinuation of bevacizumab or placebo to disease progression and death ([@bib22]), but conclusions have been criticised, due to the exclusion of several large studies with quite obvious discrepancies between PFS and OS from this meta-analysis ([@bib25]). Our findings---albeit limited by the small size of the study and its retrospective nature---suggest that high tissue AMPK expression is prognostic for improved OS in this cohort of mCRC patients.
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###### 

Click here for additional data file.

![**Patterns of phosphorylated AMPK and acetyl-CoA carboxylases expression in primary CRC samples.** Representative microphotographs of pAMPK and pACC expression in one strongly positive (CRC\#3) and one negative (CRC\#15) CRC sample; × 100 and × 200 magnifications are shown.](bjc2014274f1){#fig1}

![**Patterns of LKB1 expression in primary CRC samples.** (**A**) Representative microphotographs of LKB1 expression in samples scoring positive (CRC\#3) or negative (CRC\#28) for pAMPK; × 100 and × 200 magnifications are shown. (**B**) LKB1 and pAMPK scores in samples disclosing negative (score ⩽5) or positive (score\>5) pAMPK expression.](bjc2014274f2){#fig2}

![**Survival cumulative probabilities by pAMPK or pACC score.** Kaplan--Meier PFS (left panel) and OS (right panel) curves for patients who had positive *vs* negative pAMPK (**A**) or pACC (**B**) score.](bjc2014274f3){#fig3}

###### Association between clinico-pathological characteristics of metastatic colorectal cancer patients and immunohistochemical data

                                                             **pACC score**   **pAMPK score**                      
  --------------------------------------------- ----------- ---------------- ----------------- ------- ----- ----- -------
  **Gender**                                                                                    0.751               1.00
  Male                                           29 (60.4)         10               19                   8    21       
  Female                                         19 (39.6)         5                14                   6    13       
  **Age at diagnosis (years)**                                                                  0.757               0.756
  ⩽65                                            25 (52.1)         7                18                   8    17       
  \>65                                           23 (47.9)         8                15                   6    17       
  **Primary site**                                                                              0.724               0.729
  Colon                                          32 (66.7)         10               22                   9    23       
  Rectum                                         14 (29.2)         3                11                   3    11       
  Colon and rectum[a](#t1-fn2){ref-type="fn"}     2 (4.2)         ---               ---                 ---   ---      
  **Site of metastasis**                                                                        0.742               0.328
  Liver                                          16 (33.3)         4                12                   3    13       
  Other                                          32 (66.7)         11               21                  11    21       
  **Synchronous metastasis**                                                                    0.239               1.00
  Yes                                            39 (81.2)         14               25                  12    27       
  No                                             9 (18.7)          1                 8                   2     7       
  ***KRAS* wildtype**                                                                           0.755               1.00
  Yes                                            22 (45.8)         8                14                   6    16       
  No                                             24 (50.0)         7                17                   7    17       
  Unknown[a](#t1-fn2){ref-type="fn"}              2 (4.2)         ---               ---                 ---   ---      
  **ECOG-PS**                                                                                   0.031               0.294
  0                                              36 (75.0)         8                28                   9    27       
  1                                              12 (25.0)         7                 5                   5     7       
  **Ablation/resection of metastasis**                                                          0.004               0.206
  Yes                                            28 (58.3)         4                24                   6    22       
  No                                             20 (41.7)         11                9                   8    12       
  **Lines of treatment**                                                                        1.00                1.00
  1                                              9 (18.7)          3                 6                   3     6       
  ⩾2                                             39 (81.2)         12               27                  11    28       
  **Carcino-embrionic antigen\>30**                                                             1.00                0.321
  Yes                                            16 (33.3)         5                11                   3    13       
  No                                             31 (64.6)         10               21                  11    20       
  Unknown[a](#t1-fn2){ref-type="fn"}              1 (2.1)         ---               ---                 ---   ---      

Abbreviations: ECOG-PS=ECOG performance status; pAMPK=phosphorylated AMPK; pACC=phosphorylated acetyl-Coa carboxylase.

Excluded from the analysis.

###### Estimated 1-year overall survival and 95% confidence intervals by patient characteristics

  **Characteristics**                            ***N*** **(%)**   ***N*****. failed**   **1-year overall survival (95% CI)**   ***P*****-value**
  --------------------------------------------- ----------------- --------------------- -------------------------------------- -------------------
  **Gender**                                                                                                                          0.964
  Male                                                 29                  15                     82.7 (63.4--92.4)                      
  Female                                               19                  11                     89.5 (64.1--97.2)                      
  **Age at diagnosis (years)**                                                                                                        0.907
  ⩽65                                                  25                  13                     80.0 (58.4--91.1)                      
  \>65                                                 23                  13                     91.3 (69.5--97.7)                      
  **Primary site**                                                                                                                    0.909
  Colon                                                32                  16                     84.4 (66.4--93.2)                      
  Rectum                                               14                   8                     92.8 (59.1--99.0)                      
  Colon and rectum[a](#t2-fn2){ref-type="fn"}           2                   2                            ---                             
  **Site of metastasis**                                                                                                              0.812
  Liver                                                16                   9                     93.7 (63.2--99.1)                      
  Other                                                32                  17                     81.2 (62.9--91.1)                      
  **Synchronous metastasis**                                                                                                          0.858
  Yes                                                  39                  20                     84.6 (68.9--92.7)                      
  No                                                    9                   6                     88.9 (43.3--98.3)                      
  ***KRAS* wildtype**                                                                                                                 0.818
  Yes                                                  22                  11                     81.8 (58.5--92.7)                      
  No                                                   24                  13                     91.7 (70.6--97.8)                      
  Unknown[a](#t2-fn2){ref-type="fn"}                    2                   1                            ---                             
  **ECOG-PS**                                                                                                                         0.001
  0                                                    36                  16                     94.4 (79.6--98.6)                      
  1                                                    12                  10                     58.3 (27.0--80.1)                      
  **Ablation/ resection metastasis**                                                                                                  0.001
  Yes                                                  28                  11                     92.8 (74.3--98.2)                      
  No                                                   20                  15                     75.0 (50.0--88.7)                      
  **Lines of treatment**                                                                                                              0.050
  1                                                     9                   6                     44.4 (13.6--71.9)                      
  ⩾2                                                   39                  20                     94.9 (81.0--98.7)                      
  **Score pACC**                                                                                                                     0.0007
  ⩽5                                                   15                  12                     66.7 (37.5--84.5)                      
  \>5                                                  33                  14                     93.9 (77.9--98.4)                      
  **Score pAMPK**                                                                                                                    0.0002
  ⩽5                                                   14                  12                     71.4 (40.6--88.2)                      
  \>5                                                  34                  14                     91.2 (75.1--97.1)                      
  **Carcino-embrionic antigen \>30**                                                                                                  0.004
  Yes                                                  16                  12                     75.0 (46.3--89.8)                      
  No                                                   31                  14                     90.3 (72.9--96.8)                      
  Unknown[a](#t2-fn2){ref-type="fn"}                    1                   1                            ---                             

Abbreviations: CI=confidence interval; ECOG-PS=ECOG performance status; pAMPK=phosphorylated AMPK; pACC=phosphorylated acetyl-Coa carboxylase.

Excluded from the analysis.

###### Cox regression analysis for overall survival (multivariate analysis)

  **Characteristics**                   **Hazard ratio (95% CI)**   ***P*****-value**        **Characteristics**         **Hazard ratio (95% CI)**   ***P*****-value**
  ------------------------------------ --------------------------- ------------------- -------------------------------- --------------------------- -------------------
  **Score pAMPK**                                                       \<0.0001                  Score pACC                                              0.0007
  ⩽5                                       6.53 (2.61--16.37)                                         ⩽5                    4.34 (1.86--10.17)                
  \>5                                               1                                                \>5                             1                        
  **ECOG-PS**                                                             0.026                                                                               
  1                                         2.70 (1.13--6.48)                                                                                                 
  0                                                 1                                                                                                         
  **Carcino-embrionic antigen \>30**                                      0.008         Carcino-embrionic antigen \>30                                     0.003
  Yes                                       3.35 (1.38--8.15)                                        Yes                     3.56 (1.56--8.13)                
  No                                                1                                                 No                             1                        
  **Lines of treatment**                                                  0.007               Lines of treatment                                           0.006
  1                                        4.21 (1.49--11.94)                                         1                     4.15 (1.52--11.38)                
  ⩾2                                                1                                                 ⩾2                             1                        

Abbreviations: CI=confidence interval; ECOG-PS=ECOG performance status; pAMPK=phosphorylated AMPK; pACC=phosphorylated acetyl-Coa carboxylase.

Analysis performed on 47 patients (26 events), with all data available.

[^1]: These authors equally contributed to this work.
